Epstein Secrets

to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live EFTA00691400 If you have interest let me know Best regards Jeff Pof

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards Jeff Port (c please not

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

From: Paul Finnegan c:a To: "jeevacation®gmail.com" <jeevacation®gmail.com> Cc: Jeffrey Port < Subject: RE: Angiocrine Bioscience Update Date: Tue, 15 Mar 2016 01:09

been awarded 4 out of 4 highly competitive grants: (1) CIRM, (2) SBIR-NIH, (3) SBIR-NCI, and (4) NYSTEM—the latter, $15.8M awarded to Cornell while Angiocrine retains full commercial rights. Other highlights: • Signed a 3-year Corporate Agreement with TerumoBCT, a division of Terumo Corporation (publicl

t to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal. Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards EFTA00852543 Jeff Port

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

t to the series b, and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards Jeff Port (c) EFTA008526

30 +0000 Attachments: Angiocrine_Bioscience_Confidential_NUMBERS_deck_Jun_2015_v 150701.pptx Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan . our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards Jeff Port (c) please no

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

oscienceinvestor May_2017_v170504_1813.pdf; Angiocrinen Series_A- I_Equity_Term_Sheet_FINAL.pdf Sent from my iPhone Begin forwarded message: From: Paul Finnegan • Date: May 7, 2017 at 4:03:08 PM EDT To: " Cc: Jeffrey Port Subject: RE: Intro via Di- Jeff Port - Angiocrine Bioscience Update Dear Jeffrey,

pe this email finds all is well with you and your family. It's been about a year-and-a-half since we met at your residence in Manhattan. Since then Angiocrine team and programs have progressed forward. We moved the company to San Diego. We were awarded a $3.8M non-dilutive grant from CIRM, the State of Cal

t to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal. Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards EFTA00346026 Jeff Port

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal . Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live EFTA00346034 If you have interest let me know Best regards Jeff Port

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie